



# Zero PM

**Zero pollution of Persistent, Mobile substances**

Grant Agreement No. 101036756

## **Deliverable 9.2**

December 2021, project month three

## **HCT - Requirement No. 2**

## **Work Package 9 – Ethics**

Deliverable Work Package Leader: Sarah Hale  
Stiftelsen Norges Geotekniske Institutt (NGI)

Revision: 0 – Draft  
Dissemination level: Confidential



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101036756.

Any dissemination of results must indicate that it reflects only the author's view and that the Agency is not responsible for any use that may be made of the information it contains.

The present document has not yet received final approval from the European Commission and may be subject to changes.





## Summary

This report describes the measures taken by the H2020 ZeroPM consortium to ensure compliance of the project activities with the ethics requirement No 2 (HCT – Human cells and tissues). It includes the details on the cell/tissue types and their sources as well as information about documentation.



## Contents

<b>1</b>	<b>Human cells and tissues</b>	<b>6</b>
1.1	Humans cells/tissues available commercially	6
1.2	Human cells/tissues obtained from another project	6
<b>2</b>	<b>Documentation</b>	<b>6</b>



## 1 Human cells and tissues

Human cell lines will be used in ZeroPM and all of these lines are commercially available. Primary tissues or primary cells will not be used in ZeroPM.

### 1.1 Humans cells/tissues available commercially

The following human cell lines are currently foreseen in Task 6.3 of ZeroPM (beneficiary 3 VUA, WP6 leader).

Commercially available:

- HepaRG (ThermoFisher Scientific)
- H295R (ATCC)

Under MTA for research purposes:

- AR-EcoScreen
- ER-VM7luc4E2
- GH3.TRE-luc

In addition, task 6.3 will use high-content bioassays to evaluate the performance of the hazard characterization considering the applicability of the bioassay outcomes for predicting and/or triggering a concern for a particular adverse outcome. The type of high-content assay depends on the trigger and/or problem formulation, but may include

- Human buffy coat, which will be purchased from Sanquin blood bank.
- BeWo human placental cell line, which will be purchased from ATCC, when needed.

### 1.2 Human cells/tissues obtained from another project

Human cell lines are not expected to be obtained from another project.

## 2 Documentation

Copies of relevant documents for using, producing or collecting human cells or tissues (e.g., ethics approval, import licence, accreditation/designation/authorisation/licensing) are kept on file and will be submitted to the REA upon request.





H2020 project Zero pollution of Persistent, Mobile substances  
Grant Agreement No. 101036756